186204-77-3

Upstream product

• 123490-19-7 benzyl 2-deoxy-3,4-O-isopropylidene-2-methylene-β-L-erythro-pentopyranoside 
• 18403-22-0 (3aS,6S,7R,7aR)-6-Benzyloxy-2,2-dimethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-7-ol 
• 65247-32-7 benzyl 3,4-O-(1-methylethylidene)-β-L-erythro-pent-2-ulosylpyranoside 

Downstream Products

• 186204-79-5 C₂₃H₃₀O₈S₂ 
• 186204-80-8 (3aS,7R,7aR)-5-benzyl-2,2,7-trimethylhexahydro-[1,3]dioxolo[4,5-c]pyridine 
• 779313-82-5 (3S,4R,5R)-1-Benzyl-5-methyl-piperidine-3,4-diol 
• 401504-59-4 (3S,4R,5R)-1-[(3R,4S,5R)-1-benzyloxycarbonyl-4-hydroxy-5-hydroxymethyl-4,5'-O-isopropylidenepiperidine-3-carbonyl]-3,4-isopropylidenedioxy-5-methylpiperidine 

Relevant academic research and scientific papers

A bioisosteric oligosaccharide mimetic based on isofagomine-type monomers

A series of hydroxylated piperidine oligomers that resemble oligosaccharides is synthesised. Prepared were 5, a mimic of 3-O-L-fucopyranosyl-D-galactopyranose, 6, a mimic of 3-O-D-galactopyranosyl-D-galactopyranose and 7, a mimic of 3-O-{3-O-[3-O-(L-fucop

Synthesis of a new potent α-fucosidase inhibitor

Enantiomerically pure (3S,4R,5R)-3,4-dihydroxy-5-methylpiperidine was prepared from L-arabinose and found to be a potent human placenta α-fucosidase inhibitor.